{"id":"NCT02158546","sponsor":"Alkermes, Inc.","briefTitle":"A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study","officialTitle":"A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-05","primaryCompletion":"2015-12","completion":"2015-12","firstPosted":"2014-06-09","resultsPosted":"2019-06-25","lastUpdate":"2019-06-25"},"enrollment":447,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"ALKS 5461","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"ALKS 5461","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study will evaluate the efficacy and safety of ALKS 5461.","primaryOutcome":{"measure":"Change From Baseline to End of Treatment (Week 6) in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score","timeFrame":"Baseline and week 6","effectByArm":[{"arm":"ALKS 5461 2mg/2mg","deltaMin":-4.8,"sd":0.67},{"arm":"Placebo","deltaMin":-4.6,"sd":0.66}],"pValues":[{"comp":"OG000 vs OG001","p":"0.782"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":9},"locations":{"siteCount":58,"countries":["United States","Bulgaria"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":147},"commonTop":["Nausea","Headache","Dry mouth","Fatigue","Upper respiratory tract infection"]}}